• Something wrong with this record ?

Circulating miRNA analysis for cancer diagnostics and therapy

L. Valihrach, P. Androvic, M. Kubista

. 2020 ; 72 (-) : 100825. [pub] 20191018

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Persistent link   https://www.medvik.cz/link/bmc21012758

Successful treatment of cancer depends on early diagnosis and effective monitoring of patients' response to therapy. Traditional tools based on tumor biopsies lack the sensitivity and specificity to capture cancer development in its early phases and are not applicable for continuous monitoring. To overcome these barriers, liquid biopsies have been introduced as a minimally invasive and cost-efficient means of diagnosis with high level of specificity and sensitivity. Traditionally, liquid biopsy markers include circulating tumor cells and circulating tumor DNA. During the last decade, a new promising group of biomarkers has appeared and its utilization for cancer diagnosis and monitoring is intensively studied - the microRNAs (miRNAs). In this review, we provide a comprehensive overview of circulating miRNA analysis. We highlight the importance of sampling and quality control, discuss the technical aspects of miRNA extraction and quantification, summarize recommendations for downstream analysis and conclude with future perspectives. Taken together, we present the current state of knowledge in the field of miRNA analysis in liquid biopsies and the expected development and standardization.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012758
003      
CZ-PrNML
005      
20210507103609.0
007      
ta
008      
210420s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.mam.2019.10.002 $2 doi
035    __
$a (PubMed)31635843
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Valihrach, Lukas $u Laboratory of Gene Expression, Institute of Biotechnology CAS, BIOCEV, 252 50, Vestec, Czech Republic. Electronic address: lukas.valihrach@ibt.cas.cz
245    10
$a Circulating miRNA analysis for cancer diagnostics and therapy / $c L. Valihrach, P. Androvic, M. Kubista
520    9_
$a Successful treatment of cancer depends on early diagnosis and effective monitoring of patients' response to therapy. Traditional tools based on tumor biopsies lack the sensitivity and specificity to capture cancer development in its early phases and are not applicable for continuous monitoring. To overcome these barriers, liquid biopsies have been introduced as a minimally invasive and cost-efficient means of diagnosis with high level of specificity and sensitivity. Traditionally, liquid biopsy markers include circulating tumor cells and circulating tumor DNA. During the last decade, a new promising group of biomarkers has appeared and its utilization for cancer diagnosis and monitoring is intensively studied - the microRNAs (miRNAs). In this review, we provide a comprehensive overview of circulating miRNA analysis. We highlight the importance of sampling and quality control, discuss the technical aspects of miRNA extraction and quantification, summarize recommendations for downstream analysis and conclude with future perspectives. Taken together, we present the current state of knowledge in the field of miRNA analysis in liquid biopsies and the expected development and standardization.
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a cirkulující mikroRNA $x analýza $x izolace a purifikace $7 D000074166
650    _2
$a lidé $7 D006801
650    _2
$a tekutá biopsie $7 D000073890
650    _2
$a nádory $x diagnóza $x genetika $x terapie $7 D009369
650    _2
$a řízení kvality $7 D011786
650    _2
$a odběr biologického vzorku $x metody $7 D013048
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Androvic, Peter $u Laboratory of Gene Expression, Institute of Biotechnology CAS, BIOCEV, 252 50, Vestec, Czech Republic; Laboratory of Growth Regulators, Faculty of Science, Palacky University, 783 71, Olomouc, Czech Republic. Electronic address: peter.androvic@ibt.cas.cz
700    1_
$a Kubista, Mikael $u Laboratory of Gene Expression, Institute of Biotechnology CAS, BIOCEV, 252 50, Vestec, Czech Republic; TATAA Biocenter AB, 411 03, Gothenburg, Sweden. Electronic address: mikael.kubista@tataa.com
773    0_
$w MED00003389 $t Molecular aspects of medicine $x 1872-9452 $g Roč. 72, č. - (2020), s. 100825
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31635843 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507103608 $b ABA008
999    __
$a ok $b bmc $g 1651008 $s 1133137
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 72 $c - $d 100825 $e 20191018 $i 1872-9452 $m Molecular aspects of medicine $n Mol Aspects Med $x MED00003389
LZP    __
$a Pubmed-20210420

Find record

Citation metrics

Archiving options